Standard therapy or additionally radioactive iodine (131I) therapy; which will stop the recurrence of glioblastoma multiforme (GBM)?
Endokrynol Pol. 2024 Apr 22. doi: 10.5603/ep.98240. Online ahead of print.ABSTRACTGlioblastoma multiforme (GBM) is the most aggressive malignant brain tumour. The average survival time for a patient diagnosed with GBM, using standard treatment methods, is several months. Authors of the article pose a direct question: Is it possible to treat GBM solely with radioactive iodine (¹³¹I) therapy without employing the sodium iodide symporter (NIS) gene? After all, NIS has been detected not only in the thyroid but also in various tumours. The main author of this article (A.C.), with the assistance of her colleagues (physicians ...
Source: Endokrynologia Polska - April 22, 2024 Category: Endocrinology Authors: Agata Czarnywojtek Pawe ł Gut Kamil Dyrka Jerzy Sowi ński Nadia Sawicka-Gutaj Katarzyna Katulska Piotr Stajgis Mateusz Wykr ętowicz Jakub Moskal Jeremi Ko ściński Krzysztof Pietro ńczyk Patryk Graczyk Maciej Robert Krawczy ński Ewa Florek Ewelina S Source Type: research
UBE2C enhances temozolomide resistance by regulating the expression of p53 to induce aerobic glycolysis in glioma
In this study, we explore the role of UBE2C in regulating temozolomide (TMZ) resistance in glioma and investigate the underlying mechanisms involved. Twenty normal brain tissues and 100 glioma tissues from 50 TMZ-resistant patients and 50 TMZ-sensitive patients are included in this study. TMZ-resistant cell lines are constructed to explore the role of UBE2C in regulating glioma cell viability and TMZ resistance. Our results show that both the mRNA and protein levels of UBE2C are significantly elevated in the brain tissues of glioma patients, especially in those of TMZ-resistant patients. Consistently, UBE2C expression is m...
Source: Acta Biochimica et Biophysica Sinica - April 18, 2024 Category: Biochemistry Authors: Kun Zhou Dexin Wang Xiaolin Du Xia Feng Xiaoxi Zhu Cheng Wang Source Type: research
Identifying Diffuse Glioma Subtypes Based on Pathway Enrichment Evaluation
AbstractGliomas are highly heterogeneous in molecular, histology, and microenvironment. However, a classification of gliomas by integrating different tumor microenvironment (TME) components remains unexplored. Based on the enrichment scores of 17 pathways involved in immune, stromal, DNA repair, and nervous system signatures in diffuse gliomas, we performed consensus clustering to uncover novel subtypes of gliomas. Consistently in three glioma datasets (TCGA-glioma, CGGA325, and CGGA301), we identified three subtypes: Stromal-enriched (Str-G), Nerve-enriched (Ner-G), and mixed (Mix-G). Ner-G was charactered by low immune...
Source: Interdisciplinary Sciences, Computational Life Sciences - April 18, 2024 Category: Bioinformatics Source Type: research
GSE263890 Combined bioinformatic and clinical assay uncovers resistance and susceptibility mechanisms of human glioblastomas to temozolomide and identifies new survival biomarkers outperforming MGMT promoter methylation
Contributors : Maria Suntsova ; Alexander Modestov ; Anton BuzdinSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensGlioblastoma (GBM) is the most aggressive and lethal CNS tumor with only 14 months median overall survival after diagnosis and ∼5% 5-years survival rate. The treatment strategy is mainly surgery and/or radiation therapy, both combined with adjuvant temozolomide (TMZ) chemotherapy. TMZ treatment results in methylation of DNA purine bases, where the primary cytotoxic lesion is O6-methylguanine that can be removed by DNA rep air enzyme methylguanine methyltransferase (MGM...
Source: GEO: Gene Expression Omnibus - April 17, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Genes, Vol. 15, Pages 501: Principles in the Management of Glioblastoma
Ribeiro
Glioblastoma, the most aggressive and common malignant primary brain tumour, is characterized by infiltrative growth, abundant vascularization, and aggressive clinical evolution. Patients with glioblastoma often face poor prognoses, with a median survival of approximately 15 months. Technological progress and the subsequent improvement in understanding the pathophysiology of these tumours have not translated into significant achievements in therapies or survival outcomes for patients. Progress in molecular profiling has yielded new omics data for a more refined classification of glioblastoma. Several typical g...
Source: Genes - April 17, 2024 Category: Genetics & Stem Cells Authors: Domingos Roda Pedro Veiga Joana Barbosa Melo Isabel Marques Carreira Ilda Patr ícia Ribeiro Tags: Review Source Type: research
Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM)
ConclusionIn this trial population of predominantly fit EP, survival was similar to YP despite a proportion receiving less aggressive therapy at diagnosis and recurrence. Advancing age does not appear to be an adverse prognostic factor for glioblastoma when patients are fit for treatment, and a less aggressive approach in selected patients may not compromise outcomes. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - April 17, 2024 Category: Cancer & Oncology Source Type: research
Haploinsufficiency of phosphodiesterase 10A activates PI3K/AKT signaling independent of PTEN to induce an aggressive glioma phenotype [Research Papers]
In this study, we analyzed exome-wide human glioblastoma copy number data and found that cytoband 6q27 is an independent poor prognostic marker in multiple data sets. We then combined CRISPR–Cas9 data, human spatial transcriptomic data, and human and mouse RNA sequencing data to nominate PDE10A as a potential haploinsufficient tumor suppressor in the 6q27 region. Mouse glioblastoma modeling using the RCAS/tv-a system confirmed that Pde10a suppression induced an aggressive glioma phenotype in vivo and resistance to temozolomide and radiation therapy in vitro. Cell culture analysis showed that decreased Pde10a expressi...
Source: Genes and Development - April 17, 2024 Category: Genetics & Stem Cells Authors: Nuechterlein, N., Shelbourn, A., Szulzewsky, F., Arora, S., Casad, M., Pattwell, S., Merino-Galan, L., Sulman, E., Arowa, S., Alvinez, N., Jung, M., Brown, D., Tang, K., Jackson, S., Stoica, S., Chittaboina, P., Banasavadi-Siddegowda, Y. K., Wirsching, H. Tags: Research Papers Source Type: research
Cancers, Vol. 16, Pages 1516: Proteomic Analysis of Spatial Heterogeneity Identifies HMGB2 as Putative Biomarker of Tumor Progression in Adult-Type Diffuse Astrocytomas
gia Grosu
Arnab Chakravarti
Although grading is defined by the highest histological grade observed in a glioma, most high-grade gliomas retain areas with histology reminiscent of their low-grade counterparts. We sought to achieve the following: (i) identify proteins and molecular pathways involved in glioma evolution; and (ii) validate the high mobility group protein B2 (HMGB2) as a key player in tumor progression and as a prognostic/predictive biomarker for diffuse astrocytomas. We performed liquid chromatography tandem mass spectrometry (LC-MS/MS) in multiple areas of adult-type astrocytomas and validated our findi...
Source: Cancers - April 16, 2024 Category: Cancer & Oncology Authors: Aline P. Becker Valesio Becker Joseph McElroy Amy Webb Chunhua Han Yingshi Guo Erica H. Bell Jessica Fleming Ilinca Popp Ori Staszewski Marco Prinz Jose J. Otero Saikh Jaharul Haque Anca-Ligia Grosu Arnab Chakravarti Tags: Article Source Type: research
A Multistep In Silico Approach Identifies Potential Glioblastoma Drug Candidates via Inclusive Molecular Targeting of Glioblastoma Stem Cells
AbstractGlioblastoma (GBM) is the highest grade of glioma for which no effective therapy is currently available. Despite extensive research in diagnosis and therapy, there has been no significant improvement in GBM outcomes, with a median overall survival continuing at a dismal 15 –18 months. In recent times, glioblastoma stem cells (GSCs) have been identified as crucial drivers of treatment resistance and tumor recurrence, and GBM therapies targeting GSCs are expected to improve patient outcomes. We used a multistep in silico screening strategy to identify repurposed cand idate drugs against selected therapeutic molecu...
Source: Molecular Neurobiology - April 15, 2024 Category: Neurology Source Type: research
Preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed and resectable glioblastoma
(Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - April 15, 2024 Category: Cancer & Oncology Source Type: research
GSE263588 Comprehensive transcriptomic profiling of glioblastoma patient-derived primary tumor cell lines using bulk RNA-sequencing
Contributors : Sun H Paek ; Sanghyuk Lee ; Jong E Lee ; Yona KimSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensGlioblastoma multiforme (GBM) is a highly aggressive primary brain cancer with significant transcriptomic heterogeneity among patients. Our study aims to contribute to the field of personalized medicine for GBM patients by providing comprehensive transcriptomic profiles of GBM patients (N = 45) who underwent concurrent chemoradiotherapy with temozolomide at Seoul National University Hospital. Additionally, we include transcriptomic profiles of normal brain tissue obtained ...
Source: GEO: Gene Expression Omnibus - April 14, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Lidocaine attenuates TMZ resistance and inhibits cell migration by modulating the MET pathway in glioblastoma cells
Oncol Rep. 2024 May;51(5):72. doi: 10.3892/or.2024.8731. Epub 2024 Apr 12.ABSTRACTGlioblastoma multiforme (GBM) is the most aggressive type of malignant brain tumor. Currently, the predominant clinical treatment is the combination of surgical resection with concurrent radiotherapy and chemotherapy, using temozolomide (TMZ) as the primary chemotherapy drug. Lidocaine, a widely used amide‑based local anesthetic, has been found to have a significant anticancer effect. It has been reported that aberrant hepatocyte growth factor (HGF)/mesenchymal‑epithelial transition factor (MET) signaling plays a role in the progression o...
Source: Oncology Reports - April 12, 2024 Category: Cancer & Oncology Authors: Ming-Shan Chen Zhi-Yong Chong Cheng Huang Hsiu-Chen Huang Pin-Hsuan Su Jui-Chieh Chen Source Type: research
